Kailera Therapeutics
KLRA
100 hedge funds and large institutions have $2.57B invested in Kailera Therapeutics in 2026 Q2 according to their latest regulatory filings, with 100 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
90.21% more ownership
Funds ownership: 0% → 90.21% (+90%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bain Capital Investors
Boston,
Massachusetts
|
+$577M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$496M |
| 3 |
RTW Investments
New York
|
+$237M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$161M |
| 5 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
+$114M |
Top Sellers
KLRA Hedge Fund Activity: Q2 2026 in Review
100 of the 8,355 institutional investors tracked by Wall St. Rank reported a position in Kailera Therapeutics (KLRA) for Q2 2026, worth a combined $2.57B.
Buyers outnumbered sellers: 100 funds opened new KLRA positions and 0 closed out — a net gain of 100 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bain Capital Investors, opening a new position worth an estimated $577M.
- 100 institutional investors held Kailera Therapeutics (KLRA) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $2.57B of Kailera Therapeutics stock for Q2 2026.
- 100 funds opened new Kailera Therapeutics positions in Q2 2026 and 0 closed out, a net change of +100 holders.
- The largest Kailera Therapeutics buyer in Q2 2026 was Bain Capital Investors, an estimated $577M added.
Based on aggregated 13F filings for Q2 2026.